Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma

Overview of attention for article published in Annals of Oncology, May 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter: 15 X users
facebook: 1 Facebook page

f1000: 1 research highlight platform

Readers on

mendeley: 49 Mendeley

So far, Altmetric has seen 18 X posts from 15 X users, with an upper bound of 220,265 followers.

RT @DrAnasYounes: Phase II study of idelalisib for relapsed/refractory classical Hodgkin lymphoma. - PubMed - NCBI https://t.co/7y1R1RWPhs

Phase II study of idelalisib for relapsed/refractory classical Hodgkin lymphoma. - PubMed - NCBI https://t.co/7y1R1RWPhs

https://t.co/i0Izpb1wG1

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 14 additional X posts.